Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Qualcomm’s Q4 earnings surpassed expectations, with adjusted revenue of $11.27 billion; however, the stock fell 2%.

Qualcomm’s Q4 earnings surpassed expectations, with adjusted revenue of $11.27 billion; however, the stock fell 2%.

Bitget2025/11/06 03:48
By:Bitget

After the U.S. market closed on November 4th Eastern Time, Qualcomm released its financial report. In the third fiscal quarter, revenue reached $11.27 billion, a year-on-year increase of 10%, surpassing market expectations of $10.79 billion. Adjusted EPS was $3.00, also higher than the expected $2.88. The company projects first-quarter revenue of $11.8 billion to $12.6 billion, exceeding analysts’ expectations of $11.59 billion.

 

Although Qualcomm continues to emphasize its diversification strategy, smartphone chips still account for 62% of total revenue. In the third quarter, revenue from this segment was $6.96 billion, up 14% year-on-year. Facing growth bottlenecks in its mobile business, Qualcomm is betting on the automotive and IoT sectors.

 

Automotive chip revenue was $1.05 billion, representing a 17% year-on-year increase; IoT business revenue (including Meta’s VR/AR devices) was $1.81 billion, up 7%. While these numbers look good, their scale remains limited. The automotive segment accounts for only 9.3% of total revenue, IoT accounts for 16%, and together they are less than half the size of the smartphone chip business. After the release of the earnings report, Qualcomm shares fell 2.26% in after-hours trading.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16